Lipoprotein(a), Oxidized Phospholipids and Tensile Clot Strength Measured by Thromboelastography in Patients Undergoing Percutaneous Intervention
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026
DOI: 10.1161/atvbaha.126.324402 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026. Verfasst von Paul A Gurbel und 5 weiteren Autor:innen. Beteiligte Einrichtung: Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore and LifeBridge Health System, Baltimore, MD (P.A.G., U.S.T., K…. Hauptthemen laut MEDLINE: Blood Coagulation, Coronary Artery Disease, Ischemic Stroke, Lipoprotein(a). Die Arbeit nennt 58 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Lp(a) (lipoprotein[a]) and tensile clot strength (TCS) are distinct and independent risk factors for incident cardiovascular disease and recurrent ischemic events. Lp(a) is a carrier of oxidized phospholipids (OxPL) that contribute to its atherothrombotic properties. The current objective is to study the relationship of Lp(a) and OxPL biomarkers with TCS in patients with high-risk vascular diseases. METHODS: In a subanalysis of the ongoing MBRACE trial (Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore Racial Minority Communities), we studied Lp(a), OxPL biomarkers, and TCS in healthy subjects (n=17) and in patients with cardiovascular disease undergoing percutaneous intervention (multivessel coronary artery disease [n=60], myocardial infarction [n=86], and ischemic stroke [n=28]). Lp(a), OxPL-apoB, OxPL-apo(a), OxPL-plasminogen (OxPL-PLG), and total plasminogen were measured using enzyme-linked immunoassays. High Lp(a) was defined as ≥125 nmol/L. TCS was measured by thromboelastography, and hypercoagulability was defined by values ≥66.5 mm. RESULTS: Compared with healthy subjects, patients had higher Lp(a), OxPL-apoB, OxPL-apo(a), and TCS ( P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore and LifeBridge Health System, Baltimore, MD (P.A.G., U.S.T., K.P.B., Y.H.J.).
- Cerebrovascular, Endovascular and Skull Base Neurosurgery, Sinai Hospital of Baltimore and LifeBridge Health System, MD (W.W.A.).
- CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong and Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea (Y.H.J.).
- Division of Cardiovascular Medicine, University of California San Diego, La Jolla (S.T.).
ORCID-Profile: Paul A Gurbel, Young Hoon Jeong, Sotirios Tsimikas
Zitieren
APA
Gurbel, P. A., Tantry, U. S., Bliden, K. P., Ashley, W. W., Jeong, Y. H., & Tsimikas, S. (2026). Lipoprotein(a), Oxidized Phospholipids and Tensile Clot Strength Measured by Thromboelastography in Patients Undergoing Percutaneous Intervention. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvbaha.126.324402
Vancouver
Gurbel PA, Tantry US, Bliden KP, Ashley WW, Jeong YH, Tsimikas S. Lipoprotein(a), Oxidized Phospholipids and Tensile Clot Strength Measured by Thromboelastography in Patients Undergoing Percutaneous Intervention. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026. doi:10.1161/atvbaha.126.324402
BibTeX
@article{Gurbel2026,
author = {Gurbel, Paul A and Tantry, Udaya S and Bliden, Kevin P and Ashley, William W and Jeong, Young Hoon and Tsimikas, Sotirios},
title = {Lipoprotein(a), Oxidized Phospholipids and Tensile Clot Strength Measured by Thromboelastography in Patients Undergoing Percutaneous Intervention},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
doi = {10.1161/atvbaha.126.324402}
}
EUVIMED